Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-08-16

Clinical Trial Update: Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Everolimus for preventing acute and chronic rejection in heart transplant recipients; results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Everolimus (everolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Graft Rejection | Phase 3 | Status: COMPLETED | Results posted: 2012-08-16